NEWS PHONE

NEWS WWW

Welcome to STN International! Enter x:x LOGINID: ssspta1653hxp PASSWORD: TERMINAL (ENTER 1, 2, 3, OR ?):2 Welcome to STN International Web Page URLs for STN Seminar Schedule - N. America NEWS 1 "Ask CAS" for self-help around the clock NEWS 2 CA/CAplus records now contain indexing from 1907 to the NEWS 3 SEP 09 present INPADOC: Legal Status data reloaded DEC 08 NEWS DISSABS now available on STN 5 SEP 29 NEWS OCT 10 PCTFULL: Two new display fields added NEWS 6 NEWS 7 OCT 21 BIOSIS file reloaded and enhanced BIOSIS file segment of TOXCENTER reloaded and enhanced NEWS 8 OCT 28 MSDS-CCOHS file reloaded NEWS 9 NOV 24 CABA reloaded with left truncation NEWS 10 DEC 08 IMS file names changed NEWS 11 DEC 08 Experimental property data collected by CAS now available NEWS 12 DEC 09 in REGISTRY STN Entry Date available for display in REGISTRY and CA/CAplus DEC 09 NEWS 13 DGENE: Two new display fields added DEC 17 NEWS 14 BIOTECHNO no longer updated DEC 18 NEWS 15 CROPU no longer updated; subscriber discount no longer NEWS 16 DEC 19 available Additional INPI reactions and pre-1907 documents added to CAS NEWS 17 DEC 22 databases IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields NEWS 18 DEC 22 ABI-INFORM now available on STN NEWS 19 DEC 22 Source of Registration (SR) information in REGISTRY updated **JAN 27** NEWS 20 and searchable A new search aid, the Company Name Thesaurus, available in **JAN 27** NEWS 21 CA/CAplus German (DE) application and patent publication number format NEWS 22 FEB 05 changes MEDLINE and LMEDLINE reloaded MAR 03 NEWS 23 MEDLINE file segment of TOXCENTER reloaded NEWS 24 MAR 03 FRANCEPAT now available on STN NEWS 25 MAR 03 MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT NEWS EXPRESS MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004 NEWS HOURS STN Operating Hours Plus Help Desk Availability General Internet Information NEWS INTER Welcome Banner and News Items NEWS LOGIN

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

CAS World Wide Web Site (general information)

Direct Dial and Telecommunication Network Access to STN

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 14:46:22 ON 26 MAR 2004

=> file medline, uspatful, dgene, embase, wpids, fsta, biosis SINCE FILE COST IN U.S. DOLLARS

TOTAL SESSION

FULL ESTIMATED COST

ENTRY 0.21

0.21

FILE 'MEDLINE' ENTERED AT 14:46:40 ON 26 MAR 2004

FILE 'USPATFULL' ENTERED AT 14:46:40 ON 26 MAR 2004 CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 14:46:40 ON 26 MAR 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 14:46:40 ON 26 MAR 2004 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 14:46:40 ON 26 MAR 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 14:46:40 ON 26 MAR 2004 COPYRIGHT (C) 2004 International Food Information Service

FILE 'BIOSIS' ENTERED AT 14:46:40 ON 26 MAR 2004 COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

=> s fluorescent protein and GFP 27483 FLUORESCENT PROTEIN AND GFP

=> s modified GFP and wildtype 16 MODIFIED GFP AND WILDTYPE

=> s 11 and 12

16 L1 AND L2

=> d 13 ti abs ibib tot

ANSWER 1 OF 16 USPATFULL on STN

Transgenic plants expressing puroindolines and methods for producing TIsuch plants

This invention relates to plant cells, plant tissues or plants AB transgenic for a nucleic acid encoding a puroindoline. This invention also relates to methods of producing such transgenic plant cells, plant tissues or plants. The transgenic plants produced by the methods of this invention are useful in reducing the damage caused by plant pests, especially plant pathogens such as fungi and bacteria.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2003:284216 USPATFULL

TITLE:

Transgenic plants expressing puroindolines and methods

for producing such plants

INVENTOR(S):

Giroux, Michael J., Bozeman, MT, UNITED STATES Sherwood, John, Bozeman, MT, UNITED STATES Krishnamurthy, K., Rockville, MD, UNITED STATES Morris, Craig F., Pullman, WA, UNITED STATES

NUMBER KIND DATE ______ PATENT INFORMATION: US 2003200561 Al 20031023 US 2003-447541

A1 20030527 (10) APPLICATION INFO.:

Division of Ser. No. US 2000-489674, filed on 24 Jan RELATED APPLN. INFO.:

2000, GRANTED, Pat. No. US 6600090 Continuation-in-part

of Ser. No. US 1998-83852, filed on 22 May 1998,

GRANTED, Pat. No. US 6596930

DOCUMENT TYPE: Utility FILE SEGMENT: APPLICATION

USDA-ARS-OFFICE OF TECHNOLOGY TRANSFER, PATENT ADVISORS LEGAL REPRESENTATIVE:

OFFICE, WESTERN REGIONAL RESEARCH CENTER, 800 BUCHANAN

ST, ALBANY, CA, 94710

22 NUMBER OF CLAIMS: EXEMPLARY CLAIM: 1 LINE COUNT: 2217

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 2 OF 16 USPATFULL on STN L3

TI Methods for increasing mRNA half-life in eukaryotic cells

A method is provided whereby altered cells exhibit increased AΒ intracellular half-life of transcribed mRNAs resulting in increased levels of expressed and/or secreted proteins. The cells are genetically altered to increase the level of intracellular ribosome receptor, which

induces mRNA half-life.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:282749 USPATFULL

Methods for increasing mRNA half-life in eukaryotic TITLE:

cells

Meyer, David L., Los Angeles, CA, UNITED STATES INVENTOR(S):

The Regents of the University of California (U.S. PATENT ASSIGNEE(S):

corporation)

NUMBER KIND DATE _______ US 2003199092 A1 20031023 US 2003-342136 A1 20030113 (10) PATENT INFORMATION:

APPLICATION INFO.:

NUMBER DATE _____

US 2002-347533P PRIORITY INFORMATION: 20020111 (60)

DOCUMENT TYPE: Utility APPLICATION FILE SEGMENT:

LEGAL REPRESENTATIVE: QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX

458, ALAMEDA, CA, 94501

NUMBER OF CLAIMS: 52 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 19 Drawing Page(s)

1839 LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 3 OF 16 USPATFULL on STN L3

ΤI Better emergence characteristics and improved seedling growth under

low-light environments

This invention relates to seedlings which demonstrate better emergence AB characteristics when grown in darkness and improved seedling growth when grown under low-light levels. More specifically, the present invention relates to producing plant cells and whole plants which contain a nucleic acid sequence coding for the Coil domain as well as the sequence coding for the wildtype COP1 gene. The plants of this invention display unopened, compact leaves during seedling emergence in the darkness and reduced etiolation of seedings grown in low-levels after emergence. The invention further relates to plant breeding methods which enable the transfer of these desirable traits to wildtype plants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2003:233639 USPATFULL

TITLE:

Better emergence characteristics and improved seedling

growth under low-light environments

INVENTOR(S):

Deng, Xing Wang, Hamden, CT, UNITED STATES

McNellis, Timothy, State College, PA, UNITED STATES

Torii, Keiko, Seattle, WA, UNITED STATES

PATENT ASSIGNEE(S):

Yale University (U.S. corporation)

NUMBER KIND DATE ______ US 2003163841 A1 20030828 US 2003-386499 A1 20030313 (10)

PATENT INFORMATION:

APPLICATION INFO .:

RELATED APPLN. INFO.:

Division of Ser. No. US 1999-407956, filed on 28 Sep

1999, GRANTED, Pat. No. US 6579716

DATE NUMBER

PRIORITY INFORMATION:

US 1998-101992P 19980928 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE: MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE

NW, WASHINGTON, DC, 20004

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

38 1

NUMBER OF DRAWINGS:

10 Drawing Page(s)

LINE COUNT:

2905

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 4 OF 16 USPATFULL on STN 1.3

Transgenic plants expressing puroindolines and methods for producing ΤI

such plants

This invention relates to plant cells, plant tissues or plants AB transgenic for a nucleic acid encoding a puroindoline. This invention also relates to methods of producing such transgenic plant cells, plant tissues or plants. The transgenic plants produced by the methods of this invention are useful in reducing the damage caused by plant pests, especially plant pathogens such as fungi and bacteria.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2003:203399 USPATFULL

TITLE:

Transgenic plants expressing puroindolines and methods

for producing such plants

INVENTOR(S):

Giroux, Michael J., Bozeman, MT, United States Sherwood, John E., Bozeman, MT, United States Krishnamurthy, Krish, Bozeman, MT, United States Morris, Craig F., Pullman, WA, United States

PATENT ASSIGNEE(S):

Montana State University, Bozeman, MT, United States

(U.S. corporation)

The United States of America as represented by the Secretary of Agriculture, Washington, DC, United States

(U.S. government)

KIND DATE NUMBER _____

PATENT INFORMATION: APPLICATION INFO.:

US 6600090 B1 20030729 US 2000-489674 20000124 20000124 (9)

RELATED APPLN. INFO.:

Continuation-in-part of Ser. No. US 1998-83852, filed on 22 May 1998

DOCUMENT TYPE: FILE SEGMENT:

Utility GRANTED

PRIMARY EXAMINER: ASSISTANT EXAMINER: Fox, David T. Kubelik, Anne LEGAL REPRESENTATIVE: Morgan, Lewis & Bockius

NUMBER OF CLAIMS: 26 EXEMPLARY CLAIM: 23

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT: 2249

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 16 USPATFULL on STN

TI Better emergence characteristics and improved seedling growth under low-light environments

This invention relates to seedlings which demonstrate better emergence characteristics when grown in darkness and improved seedling growth when grown under low-light levels. More specifically, the present invention relates to producing plant cells and whole plants which contain a nucleic acid sequence coding for the Coil domain as well as the sequence coding for the wildtype COP1 gene. The plants of this invention display unopened, compact leaves during seedling emergence in the darkness and reduced etiolation of seedlings grown in low-levels after emergence. The invention further relates to plant breeding methods which enable the transfer of these desirable traits to wildtype plants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:161889 USPATFULL

TITLE: Better emergence characteristics and improved seedling

growth under low-light environments

INVENTOR(S): Deng, King Wang, Hamden, CT, United States

McNellis, Timothy, State College, PA, United States

Torii, Keiko, Seattle, WA, United States

PATENT ASSIGNEE(S): Yale University, New Haven, CT, United States (U.S.

corporation)

NUMBER DATE

PRIORITY INFORMATION: US 1998-101992P 19980928 (60) DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED
PRIMARY EXAMINER: McGarry, Sean
ASSISTANT EXAMINER: Zara, Joe

LEGAL REPRESENTATIVE: Morgan, Lewis & Bockius, LLP

NUMBER OF CLAIMS: 28 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 30 Drawing Figure(s); 13 Drawing Page(s)

LINE COUNT: 2927

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 16 USPATFULL on STN

TI Methods for the identification of reporter and target molecules using comprehensive gene expression profiles

The present invention relates to methods of identifying genes whose expression is indicative of activation of a particular biochemical or metabolic pathway or a common set of biological reactions or functions in a cell ("regulon indicator genes") The present invention provides an example of such an indicator gene. The present invention also relates to methods of partially characterizing a gene of unknown function by determining which biological pathways, reactions or functions its expression is associated with, thereby placing the gene within a functional genetic group or "regulon". These partially characterized genes may be used to identify desirable therapeutic targets of

biological pathways of interest ("regulon target genes") The present invention provides examples of such target genes. Methods for identifying effectors (activators and inhibitors) of regulon target genes are provided. The present invention also provides examples of regulon target gene inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2003:135137 USPATFULL

TITLE:

Methods for the identification of reporter and target molecules using comprehensive gene expression profiles

INVENTOR(S):

Ashby, Matthew, Mill Valley, CA, UNITED STATES Scherer, Stewart, Moraga, CA, UNITED STATES Phillips, John W., Kirkland, WA, UNITED STATES Ziman, Michael, Seattle, WA, UNITED STATES

Marini, Nicholas, San Francisco, CA, UNITED STATES

PATENT ASSIGNEE(S):

Rosetta Inpharmatics, Inc. (U.S. corporation)

DATE NUMBER KIND

PATENT INFORMATION:

US 2003093226 A1 20030515 US 2002-205841 A1 20020726

APPLICATION INFO.:

(10)

RELATED APPLN. INFO.:

Continuation of Ser. No. US 2000-540806, filed on 31

Mar 2000, ABANDONED

NUMBER DATE _____

PRIORITY INFORMATION:

US 1999-127223P 19990331 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW

YORK, NY, 100362711

NUMBER OF CLAIMS:

EXEMPLARY CLAIM: NUMBER OF DRAWINGS:

87 Drawing Page(s)

LINE COUNT:

3369

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 7 OF 16 USPATFULL on STN

Methods for identifying agents that induce a cellular phenotype, and TΙ

compositions thereof

The present invention is directed to methods for performing negative AΒ selection assays leading to the identification of cytostatic or cytotoxic agents that cause a lethal phenotype. The invention is useful also for evaluation of conditional cytotoxicity and cell-specific cytotoxicity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2003:78469 USPATFULL

TITLE:

Methods for identifying agents that induce a cellular

phenotype, and compositions thereof

INVENTOR(S):

Kamb, Carl Alexander, Salt Lake City, UT, UNITED STATES

(10)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003054389	A1	20030320	
APPLICATION INFO :	US 2002-196408	A 1	20020716	(

NUMBER DATE

PRIORITY INFORMATION: US 2001-309088P 20010731 (60) US 2001-305711P 20010716 (60)

US 2001-305712P 20010716 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT: APPLICATION

MARSHALL, GERSTEIN & BORUN, 6300 SEARS TOWER, 233 SOUTH LEGAL REPRESENTATIVE:

WACKER, CHICAGO, IL, 60606-6357

NUMBER OF CLAIMS: 15 EXEMPLARY CLAIM: 1

approaches.

NUMBER OF DRAWINGS: 28 Drawing Page(s)

LINE COUNT: 4473

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 8 OF 16 USPATFULL on STN T.3

Synthetic DNA encoding an orange seapen-derived green ΤI fluorescent protein with codon preference of mammalian

expression systems and biosensors

Synthetic versions of a full length and termini truncated humanized AΒ green fluorescent protein based on Ptilosarcus qurneyi are disclosed which have been modified to the favored or most favored codons for mammalian expression systems. The disclosed encoded protein has 239 amino acid residues compared with the wild type Ptilosarcus gurneyi which has 238 amino acids. In the present invention, a valine residue has been added at the second position from the amino terminus and codon preference bias has been changed in a majority of the wild type codons of Ptilosarcus gurneyi fluorescent protein. The humanized Ptilosarcus gurneyi green fluorescent protein is useful as a fluorescent tag for monitoring the activities of its fusion partners using imaging based

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

2002:343947 USPATFULL ACCESSION NUMBER:

Synthetic DNA encoding an orange seapen-derived green TITLE:

fluorescent protein with codon

preference of mammalian expression systems and

biosensors

INVENTOR(S): Chen, Yih-Tai, Gibsonia, PA, UNITED STATES

Cao, Longguang, Boulder, CO, UNITED STATES

NUMBER KIND DATE ______ US 2002197673 PATENT INFORMATION: A1 20021226 20011015 US 2001-977897 (9) APPLICATION INFO.: A1

NUMBER DATE -----US 2001-297645P PRIORITY INFORMATION: 20010612 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: CRAIG G. COCHENOUR, BUCHANAN INGERSOLL, P.C., ONE

OXFORD CENTRE, 20th FLOOR, 301 GRANT STREET,

PITTSBURGH, PA, 15219

NUMBER OF CLAIMS: 45 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 20 Drawing Page(s)

LINE COUNT: 1714

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 16 USPATFULL on STN

Tandem fluorescent protein constructs ΤI

This invention provides tandem fluorescent protein ΔR construct including a donor fluorescent protein moiety, an acceptor fluorescent protein moiety and a linker moiety that couples the donor and acceptor moieties. The donor and acceptor moieties exhibit fluorescence resonance energy transfer which is eliminated upon cleavage. The constructs are useful in enzymatic assays.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

2002:294631 USPATFULL ACCESSION NUMBER:

TITLE: Tandem fluorescent protein

constructs

Tsien, Roger Y., La Jolla, CA, UNITED STATES INVENTOR(S):

Heim, Roger, Del Mar, CA, UNITED STATES

Cubitt, Andrew, San Diego, CA, UNITED STATES

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (U.S. PATENT ASSIGNEE(S):

corporation)

NUMBER KIND DATE _______

PATENT INFORMATION:

APPLICATION INFO.:

US 2002164674 A1 20021107 US 2002-57505 A1 20020125 (10)

RELATED APPLN. INFO.:

Continuation of Ser. No. US 1999-396003, filed on 13

Sep 1999, PENDING Continuation of Ser. No. US

1997-792553, filed on 31 Jan 1997, GRANTED, Pat. No. US

5981200 Continuation-in-part of Ser. No. US 1996-594575, filed on 31 Jan 1996, PENDING

DOCUMENT TYPE:

Utility APPLICATION

FILE SEGMENT: LEGAL REPRESENTATIVE:

Lisa A. Haile, J.D., Ph.D., GRAY CARY WARE &

FREIDENRICH LLP, Suite 1100, 4365 Executive Drive, San

Diego, CA, 92121-2133

NUMBER OF CLAIMS:

57 1

EXEMPLARY CLAIM: NUMBER OF DRAWINGS:

10 Drawing Page(s)

LINE COUNT:

1845

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 10 OF 16 USPATFULL on STN L3

Identification of drugs and drug targets by detection of the stress ΤI

response

AΒ The invention features methods of high throughput screening of candidate drug agents and rapid identification of drug targets by examining induction of the stress response in a host cell, e.g., the stress response in wildtype host cells and/or in host cells that differ in target gene product dosage (e.g., host cells that have two copies of a drug target gene product-encoding sequence relative to one copy). In general, induction of the stress response in wildtype host cells indicates that a candidate agent has activity of the drug. Induction of a relatively lower or undetectable stress response in a host cell comprising an alteration in gene product dosage indicates that the host cell is drug-sensitive and is altered in a gene product that plays a role in resistance to the drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2002:171871 USPATFULL

TITLE:

Identification of drugs and drug targets by detection

of the stress response

INVENTOR(S):

Davis, Ronald W., Palo Alto, CA, UNITED STATES Giaever, Guri N., Palo Alto, CA, UNITED STATES

NUMBER KIND DATE _____ US 2002090620 A1 20020711 US 2001-898745 A1 20010703 (9) PATENT INFORMATION: APPLICATION INFO.:

> NUMBER DATE

PRIORITY INFORMATION: US 2000-218288P 20000714 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION LEGAL REPRESENTATIVE: Carol L. Francis, Bozicevic, Field and Francis LLP, Suite 200, 200 Middlefield Road, Menlo Park, CA, 94025

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 1 Drawing Page(s)

LINE COUNT:

1530

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 11 OF 16 USPATFULL on STN T.3

Methods for validating polypeptide targets that correlate to cellular TΤ

phenotypes

Generally applicable methods for identifying physiologically relevant AΒ endogenous target molecules, are provided. The methods use both protein interaction assay steps and phenotypic assay steps. In some embodiments, protein interactions are detected utilizing yeast two hybrid techniques.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2002:85148 USPATFULL

TITLE:

Methods for validating polypeptide targets that

correlate to cellular phenotypes

INVENTOR (S):

Kamb, Carl Alexander, Salt Lake City, UT, UNITED STATES Caponigro, Giordano Michael, Salt Lake City, UT, UNITED

STATES

Teng, David Heng-Fai, Salt Lake City, UT, UNITED STATES

Sandrock, Tanya Marie, Salt Lake City, UT, UNITED

STATES

Stump, Mark, Salt Lake City, UT, UNITED STATES

NUMBER	KIND	DATE

PATENT INFORMATION: APPLICATION INFO .:

US 2002045188 **A1** 20020418 20010525 US 2001-865644 A1

RELATED APPLN. INFO.:

Continuation-in-part of Ser. No. US 1998-193759, filed on 17 Nov 1998, ABANDONED Continuation-in-part of Ser.

(9)

No. WO 2001-US9927409, filed on 10 Apr 2001, UNKNOWN

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

Li-Hsien Rin-Laures, MD, MARSHALL, O'TOOLE, GERSTEIN,

MURRAY & BORUN, 6300 Sears Tower, 233 South Wacker

Drive, Chicago, IL, 60606-6402

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

24

NUMBER OF DRAWINGS:

8 Drawing Page(s)

LINE COUNT:

2579

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 12 OF 16 USPATFULL on STN 1.3

Mutants of the green fluorescent protein having TT

improved fluorescent properties at 37°

The present invention relates to mutants of the green ΔR

fluorescent protein having improved fluorescent

properties at 37° C. The mutants provide for improved methods of monitoring gene expression, e.g., for use as cell markers or protein expression indicators in prokaryotic and, especially, eucaryotic systems where the standard physiological temperature is 37° C.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2000:98547 USPATFULL

TITLE:

Mutants of the green fluorescent

protein having improved fluorescent properties

at 37°

INVENTOR(S):

Michaels, Mark, Encino, CA, United States

PATENT ASSIGNEE(S):

Amgen Inc., Thousand Oaks, CA, United States (U.S.

corporation)

NUMBER KIND DATE ______

PATENT INFORMATION:

US 6096865

20000801

APPLICATION INFO.:

US 1996-643704

19960506 (8)

DOCUMENT TYPE: FILE SEGMENT:

Utility Granted

PRIMARY EXAMINER:

Spector, Lorraine

ASSISTANT EXAMINER:

LEGAL REPRESENTATIVE:

Kaufman, Claire M.

NUMBER OF CLAIMS:

Crandall, Craig A., Levy, Ron K., Odre, Steven M.

EXEMPLARY CLAIM:

1

LINE COUNT:

1271

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 16 USPATFULL on STN

Humanized green fluorescent protein genes and TI

methods

AB

Disclosed are synthetic and "humanized" versions of green

fluorescent protein (GFP) genes adapted for

high level expression in mammalian cells, especially those of human origin. Base substitutions are made in various codons in order to change the codon usage to one more appropriate for expression in mammalian cells. Recombinant vectors carrying such humanized genes are also disclosed. In addition, various methods for using the efficient expression of humanized GFP in mammalian cells and in animals are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2000:12655 USPATFULL

TITLE:

Humanized green fluorescent protein

genes and methods

INVENTOR (S):

Muzyczka, Nicholas, Gainesville, FL, United States Zolotukhin, Sergei, Gainesville, FL, United States Hauswirth, William, Gainesville, FL, United States University of Florida, Gainesville, FL, United States

PATENT ASSIGNEE(S):

(U.S. corporation)

NUMBER KIND DATE ______

PATENT INFORMATION:

US 1997-893327 US 6020192

APPLICATION INFO.: RELATED APPLN. INFO.:

Continuation-in-part of Ser. No. US 1997-588201, filed

20000201 19970716

(8)

on 18 Jan 1997

DOCUMENT TYPE:

Utility Granted

FILE SEGMENT: PRIMARY EXAMINER:

Degen, Nancy Wang, Andrew

ASSISTANT EXAMINER: LEGAL REPRESENTATIVE:

Arnold, White & Durkee

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

11

NUMBER OF DRAWINGS:

29 Drawing Figure(s); 22 Drawing Page(s)

LINE COUNT:

4342

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 14 OF 16 USPATFULL on STN L3

Tandem fluorescent protein constructs TΙ

This invention provides tandem fluorescent protein AB construct including a donor fluorescent protein moiety, an acceptor fluorescent protein moiety and a

linker moiety that couples the donor and acceptor moieties. The donor and acceptor moieties exhibit fluorescence resonance energy transfer which is eliminated upon cleavage. The constructs are useful in

enzymatic assays.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1999:141607 USPATFULL ACCESSION NUMBER:

Tandem fluorescent protein TITLE:

constructs

Tsien, Roger Y., La Jolla, CA, United States INVENTOR (S):

Heim, Roger, Del Mar, CA, United States

Cubitt, Andrew, San Diego, CA, United States

The Regents of the University of California, Oakland, PATENT ASSIGNEE(S):

CA, United States (U.S. corporation) Aurora Biosciences Corporation, La Jolla, CA, United

States (U.S. corporation)

KIND DATE NUMBER

PATENT INFORMATION:

US 5981200 19991109 US 1997-792553 19970131

APPLICATION INFO .:

19970131 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-594575, filed

on 31 Jan 1996

DOCUMENT TYPE: FILE SEGMENT: PRIMARY EXAMINER: Utility Granted Feisee, Lila Pak, Michael

ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: Fish & Richardson P.C.

NUMBER OF CLAIMS:

EXEMPLARY CLAIM: NUMBER OF DRAWINGS:

10 Drawing Figure(s); 10 Drawing Page(s)

LINE COUNT:

1903

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 15 OF 16 USPATFULL on STN L3

Humanized green fluorescent protein genes and TΙ

methods

Disclosed are synthetic and "humanized" versions of green AB

fluorescent protein (GFP) genes adapted for high level expression in mammalian cells, especially those of human origin. Base substitutions are made in various codons in order to change the codon usage to one more appropriate for expression in mammalian cells. Recombinant vectors carrying such humanized genes are also disclosed. In addition, various methods for using the efficient expression of humanized GFP in mammalian cells and in animals

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

are described.

1999:128366 USPATFULL

TITLE:

Humanized green fluorescent protein

genes and methods

INVENTOR(S):

Zolotukhin, Sergei, Gainesville, FL, United States Muzyczka, Nicholas, Gainesville, FL, United States Hauswirth, William W., Gainesville, FL, United States The University of Florida Research Foundation Inc.,

PATENT ASSIGNEE(S):

Gainesville, FL, United States (U.S. corporation)

KIND DATE NUMBER _____ US 5968750 19991019 US 1998-169605 19981009 (9)

PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.:

Division of Ser. No. US 1996-588201, filed on 18 Jan

1996, now patented, Pat. No. US 5874304

DOCUMENT TYPE: Utility Granted FILE SEGMENT:

Elliott, George P. PRIMARY EXAMINER: ASSISTANT EXAMINER: Wang, Andrew

LEGAL REPRESENTATIVE:

Williams, Morgan & Amerson

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

1

NUMBER OF DRAWINGS:

11 Drawing Figure(s); 19 Drawing Page(s)

LINE COUNT:

3839

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 16 OF 16 USPATFULL on STN

TI Humanized green fluorescent protein genes and

methods

AB Disclosed are synthetic and "humanized" versions of green

fluorescent protein (GFP) genes adapted for

high level expression in mammalian cells, especially those of human origin. Base substitutions are made in various codons in order to change the codon usage to one more appropriate for expression in mammalian cells. Recombinant vectors carrying such humanized genes are also disclosed. In addition, various methods for using the efficient expression of humanized GFP in mammalian cells and in animals are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

1999:24523 USPATFULL

TITLE:

Humanized green fluorescent protein

genes and methods

INVENTOR(S):

Zolotukhin, Sergei, Gainesville, FL, United States Muzyczka, Nicholas, Gainesville, FL, United States Hauswirth, William W., Gainesville, FL, United States

PATENT ASSIGNEE(S):

University of Florida Research Foundation, Inc., Gainesville, FL, United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION:

US 5874304

19990223

APPLICATION INFO.:

US 1996-588201 Utility 19960118 (8)

DOCUMENT TYPE: FILE SEGMENT:

Granted

PRIMARY EXAMINER:

Degen, Nancy

ASSISTANT EXAMINER:

Wang, Andrew

LEGAL REPRESENTATIVE:

Arnold, White & Durkee

NUMBER OF CLAIMS:

81

EXEMPLARY CLAIM:

1

NUMBER OF DRAWINGS:

26 Drawing Figure(s); 19 Drawing Page(s)

LINE COUNT:

3932

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 14:46:22 ON 26 MAR 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT 14:46:40 ON 26 MAR 2004

L1 27483 S FLUOR

27483 S FLUORESCENT PROTEIN AND GFP

L2 16 S MODIFIED GFP AND WILDTYPE

L3 16 S L1 AND L2

=> s l1 and "S175"

L4 51 L1 AND "S175"

=> s 14 and "F64"

L5 4 L4 AND "F64"

=> d 15 ti abs ibib tot

L5 ANSWER 1 OF 4 USPATFULL on STN

TI Proteins associated with cell growth, differentiation, and death

The invention provides human proteins associated with cell growth, AB differentiation, and death (CGDD) and polynucleotides which identify and encode CGDD. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of CGDD.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2003:282632 USPATFULL

TITLE:

Proteins associated with cell growth, differentiation,

and death

INVENTOR(S):

Azimzai, Yalda, Oakland, CA, UNITED STATES Au-Young, Janice, Brisbane, CA, UNITED STATES Batra, Sajeev, Oakland, CA, UNITED STATES Baughn, Mariah R., San Leandro, CA, UNITED STATES Becha, Shanya D., Castro Valley, CA, UNITED STATES Borowsky, Mark L., Redwood City, CA, UNITED STATES Burford, Neil, Durham, CT, UNITED STATES Ding, Li, Creve Coeur, MO, UNITED STATES Elliott, Vicki S., San Jose, CA, UNITED STATES Emerling, Brooke M., Chicago, IL, UNITED STATES Gandhi, Ameena R., San Francisco, CA, UNITED STATES Gietzen, Kimberly J., San Jose, CA, UNITED STATES Griffin, Jennifer A., San Jose, CA, UNITED STATES Hafalia, April J. A., Santa Clara, CA, UNITED STATES Honchell, Cynthia D., San Carlos, CA, UNITED STATES Lal, Preeti G., Santa Clara, CA, UNITED STATES Lee, Soo Yeun, Daly City, CA, UNITED STATES Lu, Dyung Aina M., San Jose, CA, UNITED STATES Arvizu, Chandra S., San Jose, CA, UNITED STATES Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES Reddy, Roopa M., Sunnyvale, CA, UNITED STATES Sanjanwala, Madhusudan S., Los Altos, CA, UNITED STATES Tang, Y. Tom, San Jose, CA, UNITED STATES Chawla, Narinder K., Union City, CA, UNITED STATES Wang, Yu-Mei E., Mountain View, CA, UNITED STATES Warren, Bridget A., Encinitas, CA, UNITED STATES Xu, Yuming, Mountain View, CA, UNITED STATES Yang, Junming, San Jose, CA, UNITED STATES Yao, Monique G., Carmel, IN, UNITED STATES Yue, Henry, Sunnyvale, CA, UNITED STATES Zebarjadian, Yeganeh, San Francisco, CA, UNITED STATES Incyte Genomics, Inc., Palo Alto, CA (U.S. corporation)

PATENT ASSIGNEE(S):

NUMBER KIND DATE ______

PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: US 2003198975 A1 20031023 US 2002-287218 A1 20021031 (10)

Continuation of Ser. No. WO 2002-US11152, filed on 5

DATE

Apr 2002, PENDING

NUMBER

PRIORITY INFORMATION:

WO	2002-US11152	20020405	
US	2002-349705P	20020115	(60)
US	2001-295263P	20010601	(60)
US	2001-295340P	20010601	(60)
US	2001-293727P	20010525	(60)
US	2001-291846P	20010518	(60)
US	2001-291662P	20010516	(60)
US	2001-287228P	20010427	(60)
US	2001-286820P	20010426	(60)
US	2001-283294P	20010411	(60)
US	2001-282110P	20010406	(60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

INCYTE CORPORATION (formerly known as Incyte, Genomics,

Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304

NUMBER OF CLAIMS:

97 1

EXEMPLARY CLAIM: LINE COUNT:

10940

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 4 USPATFULL on STN

TI Fluorescent proteins

AB The present invention provides novel engineered derivatives of green

fluorescent protein (GFP) which have an

amino acid sequence which is modified by amino acid substitution compared with the amino acid sequence of wild type Green

Fluorescent Protein. The modified GFPs exhibit

enhanced fluorescence relative to wtGFP when expressed in non-homologous cells at temperatures above 30° C., and when excited at about 490 nm compared to the parent proteins, i.e. wtGFP. An example of a preferred protein is F64L-S175G-E222G-GFP. The modified GFPs provide a means for detecting GFP reporters in mammalian cells at lower levels of expression and/or increased sensitivity relative to wtGFP. This greatly improves the usefulness of fluorescent proteins in studying cellular functions in living cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2003:251073 USPATFULL

TITLE:

Fluorescent proteins

INVENTOR(S):

Stubbs, Simon Lawrence John, Amersham Buckinghamshire,

UNITED KINGDOM

Jones, Anne Elizabeth, Amersham Buckinghamshire, UNITED

KINGDOM

Michael, Nigel Paul, Amersham Buckinghamshire, UNITED

KINGDOM

Thomas, Nicholas, Amersham Buckinghamshire, UNITED

KINGDOM

NUMBER	KIND	DATE	
US 2003175859	A1	20030918	
US 2001-967301	A1	20010928	(9)

PATENT INFORMATION: APPLICATION INFO.:

NUMBER DATE

PRIORITY INFORMATION:

GB 2001-9858

20010423

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

AMERSHAM BIOSCIENCES, PATENT DEPARTMENT, 800 CENTENNIAL

AVENUE, PISCATAWAY, NJ, 08855

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

24

NUMBER OF DRAWINGS:

7 Drawing Page(s)

LINE COUNT:

1284

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 4 USPATFULL on STN

TI Polynucleotide encoding a novel immunoglobulin superfamily member,

APEX4, and variants and splice variants thereof

AB The present invention provides novel polynucleotides encoding APEX4 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants and splice variants of APEX4 polypeptides, APEX4v1 and APEX4sv1, respectively. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates

to diagnostic and therapeutic methods for applying these novel APEX4, APEX4v1, and APEX4sv1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2003:133932 USPATFULL

TITLE:

Polynucleotide encoding a novel immunoglobulin superfamily member, APEX4, and variants and splice

variants thereof

INVENTOR (S):

Finger, Joshua N., San Marcos, CA, UNITED STATES

	NUMBER	KIND	DATE
ATENT INFORMATION:	US 2003092017	A1	20030515
NOT TORMTON THEO	110 2002-104943	Δ1	20020322

PA' APPLICATION INFO .:

(10) 20020322 US 2002-104943

DATE NUMBER US 2001-278037P 20010322 (60)

PRIORITY INFORMATION:

US 2001-281223P 20010403 (60)

DOCUMENT TYPE: FILE SEGMENT:

Utility

LEGAL REPRESENTATIVE:

APPLICATION STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT

DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000

NUMBER OF CLAIMS:

EXEMPLARY CLAIM: NUMBER OF DRAWINGS:

13 Drawing Page(s)

LINE COUNT:

13219

19

1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

- ANSWER 4 OF 4 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN L5
- Novel fluorescent protein derived from green fluorescent protein useful as a transfection marker, has different excitation spectrum and/or emission spectrum compared with wild-type green fluorescent protein.
- 2003-095652 [09] WPIDS AN
- AB 2374868 A UPAB: 20030206

NOVELTY - A fluorescent protein (I) derived from green fluorescent protein (GFP) or any functional GFP analog, has an amino acid sequence which is modified by amino acid substitution at position F64, at position S65 or E222, and at position S175 compared with the amino acid sequence of wild-type GFP, and has different excitation spectrum and/or emission spectrum compared with wild-type GFP, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a fusion compound (II) comprising a protein of interest fused to (I);
- (2) a nucleic acid molecule (III) comprising a nucleotide sequence encoding (I) or (II);
- (3) an expression vector (IV) comprising suitable expression control sequences operably linked to (III); and
- (4) a host cell (V) transformed or transfected with a DNA construct comprising (IV).
- $\mathtt{USE}\ \bar{\ }$ (III) is useful for measuring the expression of a protein of interest in a cell, by introducing (III) into a cell, where (III) is operably linked to and under the control of an expression control sequence which moderates expression of the protein of interest, culturing the cell under conditions suitable for the expression of the protein of interest, and detecting the fluorescence emission of GFP or functional GFP analog. (III) is useful for determining the cellular and/or

extracellular localization of a protein of interest. (III) is also useful for comparing the effect of one or more test substance(s) on the expression and/or localization of one or more different protein(s) of interest in a cell. The method involves:

- (a) introducing into a cell, (III) operably linked to and under the control of a first expression control sequence and optionally fused to a nucleotide sequence encoding a fusion protein of interest, and optionally, at least one different nucleic acid molecule encoding a protein reporter molecule fused to a different protein of interest, where the nucleic acid molecule is operably linked to and under the control of a second expression control sequence, and the protein reporter molecule has or is capable of generating an emission signal which is spectrally distinct from that of GFP or functional GFP analog;
- (b) culturing the cells under conditions suitable for the expression of the protein(s) of interest in the presence and absence of the test substance(s);
- (c) determining the expression and/or localization of the protein(s) in the cells by detecting the fluorescence emission by optical means; and
- (d) comparing the fluorescence emission obtained in the presence and absence of the test substance(s).

The samples of the cells in a fluid medium are introduced into separate vessels for each of the test substances to be studied (all claimed).

(I) is useful as a non-toxic marker for selection of transfected cells, as a protein label in living and fixed cells, as a marker in cell or organelle fusion, for visualizing translocation of intracellular proteins to a specific organelle, as a secretion marker, as genetic reporter or protein tag for protein and gene expression in transgenic animals, as a cell or organelle integrity marker, as a transfection marker, as a marker to be used in combination with fluorescent activated cell sorting (FACS), as real-time probe working at near physiological concentrations, for performing transposon vector mutagenesis, and as a reporter for bacterial detection.

ADVANTAGE - (I) exhibits enhanced fluorescence relative to wild type GFP, when expressed in non-homologous cells at temperatures above 30 deg. C, and excited at 490 nm. (I) detects GFP reporters in mammalian cells at lower levels of expression with increased sensitivity relative to wild type GFP.

Dwg.0/7

ACCESSION NUMBER: 2003-095652 [09] WPIDS

DOC. NO. NON-CPI: N2003-075841

DOC. NO. CPI: C2003-024324

TITLE: Novel fluorescent protein derived from green fluorescent protein useful

as a transfection marker, has different excitation spectrum and/or emission spectrum compared with wild-type

green fluorescent protein.

DERWENT CLASS: B04 D16 S03

INVENTOR(S): JONES, A E; MICHAEL, N P; STUBBS, S L J; THOMAS, N PATENT ASSIGNEE(S): (AMSH) AMERSHAM BIOSCIENCES UK LTD; (AMSH) AMERSHAM PHARMACIA BIOTECH UK LTD; (JONE-I) JONES A E; (MICH-I)

MICHAEL N P; (STUB-I) STUBBS S L J; (THOM-I) THOMAS N

COUNTRY COUNT: 98

PATENT INFORMATION:

PATENT NO KIND DATE WEEK LA PG

GB 2374868 A 20021030 (200309)* 52

WO 2002085936 A1 20021031 (200309) EN

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO

RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

GB 2374868 B 20030709 (200353)

US 2003175859 A1 20030918 (200362)

EP 1381625 A1 20040121 (200410) EN

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR

APPLICATION DETAILS:

PATENT NO KIND	APPLICATION	DATE
GB 2374868 A WO 2002085936 A1 GB 2374868 B US 2003175859 A1 EP 1381625 A1	GB 2001-23288 WO 2001-GB4363 GB 2001-23288 US 2001-967301 EP 2001-972260 WO 2001-GB4363	20010928 20010928 20010928 20010928 20010928 20010928

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1381625	A1 Based on	WO 2002085936

PRIORITY APPLN. INFO: GB 2001-9858 20010423

=> d his

(FILE 'HOME' ENTERED AT 14:46:22 ON 26 MAR 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT 14:46:40 ON 26 MAR 2004

L1 27483 S FLUORESCENT PROTEIN AND GFP

L2 16 S MODIFIED GFP AND WILDTYPE

L3 16 S L1 AND L2

L4 51 S L1 AND "S175"

L5 4 S L4 AND "F64"

=> s 14 and E222

'E222' NOT FOUND

The E# entered is not currently defined.

=> s 14 and "E222"

L6 2 L4 AND "E222"

=> s 11 and "S65"

L7 66 L1 AND "S65"

=> d 16 ti abs ibib tot

L6 ANSWER 1 OF 2 USPATFULL on STN

TI Fluorescent proteins

The present invention provides novel engineered derivatives of green fluorescent protein (GFP) which have an amino acid sequence which is modified by amino acid substitution compared with the amino acid sequence of wild type Green Fluorescent Protein. The modified GFPs exhibit enhanced fluorescence relative to wtGFP when expressed in non-homologous cells at temperatures above 30° C., and when excited at about 490 nm compared to the parent proteins, i.e. wtGFP. An example of a preferred protein is F64L-S175G-E222G-GFP. The modified GFPs provide a means for detecting GFP reporters in mammalian cells at lower levels of expression and/or increased sensitivity relative to

wtGFP. This greatly improves the usefulness of fluorescent proteins in studying cellular functions in living cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2003:251073 USPATFULL

TITLE:

Fluorescent proteins

INVENTOR(S):

Stubbs, Simon Lawrence John, Amersham Buckinghamshire,

UNITED KINGDOM

Jones, Anne Elizabeth, Amersham Buckinghamshire, UNITED

KINGDOM

Michael, Nigel Paul, Amersham Buckinghamshire, UNITED

Thomas, Nicholas, Amersham Buckinghamshire, UNITED

KINGDOM

NUMBER KIND DATE US 2003175859 A1 20030918 US 2001-967301 A1 20010928 (9) PATENT INFORMATION: APPLICATION INFO .:

> NUMBER DATE ______

PRIORITY INFORMATION:

GB 2001-9858 20010423

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

AMERSHAM BIOSCIENCES, PATENT DEPARTMENT, 800 CENTENNIAL

AVENUE, PISCATAWAY, NJ, 08855

NUMBER OF CLAIMS:

EXEMPLARY CLAIM: NUMBER OF DRAWINGS:

7 Drawing Page(s)

LINE COUNT:

1284

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

- ANSWER 2 OF 2 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
- Novel fluorescent protein derived from green

fluorescent protein useful as a transfection marker, has

different excitation spectrum and/or emission spectrum compared with wild-type green fluorescent protein.

2003-095652 [09] WPIDS ΑN

2374868 A UPAB: 20030206 AB

NOVELTY - A fluorescent protein (I) derived from green fluorescent protein (GFP) or any functional GFP analog, has an amino acid sequence which is modified by amino acid substitution at position F64, at position S65 or E222, and

at position \$175 compared with the amino acid sequence of wild-type GFP, and has different excitation spectrum and/or emission spectrum compared with wild-type GFP, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a fusion compound (II) comprising a protein of interest fused to (I);
- (2) a nucleic acid molecule (III) comprising a nucleotide sequence encoding (I) or (II);
- (3) an expression vector (IV) comprising suitable expression control sequences operably linked to (III); and
- (4) a host cell (V) transformed or transfected with a DNA construct comprising (IV).

USE - (III) is useful for measuring the expression of a protein of interest in a cell, by introducing (III) into a cell, where (III) is operably linked to and under the control of an expression control sequence which moderates expression of the protein of interest, culturing the cell under conditions suitable for the expression of the protein of interest, and detecting the fluorescence emission of GFP or functional GFP analog. (III) is useful for determining the cellular and/or

extracellular localization of a protein of interest. (III) is also useful for comparing the effect of one or more test substance(s) on the expression and/or localization of one or more different protein(s) of interest in a cell. The method involves:

- (a) introducing into a cell, (III) operably linked to and under the control of a first expression control sequence and optionally fused to a nucleotide sequence encoding a fusion protein of interest, and optionally, at least one different nucleic acid molecule encoding a protein reporter molecule fused to a different protein of interest, where the nucleic acid molecule is operably linked to and under the control of a second expression control sequence, and the protein reporter molecule has or is capable of generating an emission signal which is spectrally distinct from that of GFP or functional GFP analog;
- (b) culturing the cells under conditions suitable for the expression of the protein(s) of interest in the presence and absence of the test substance(s);
- (c) determining the expression and/or localization of the protein(s) in the cells by detecting the fluorescence emission by optical means; and
- (d) comparing the fluorescence emission obtained in the presence and absence of the test substance(s).

The samples of the cells in a fluid medium are introduced into separate vessels for each of the test substances to be studied (all claimed).

(I) is useful as a non-toxic marker for selection of transfected cells, as a protein label in living and fixed cells, as a marker in cell or organelle fusion, for visualizing translocation of intracellular proteins to a specific organelle, as a secretion marker, as genetic reporter or protein tag for protein and gene expression in transgenic animals, as a cell or organelle integrity marker, as a transfection marker, as a marker to be used in combination with fluorescent activated cell sorting (FACS), as real-time probe working at near physiological concentrations, for performing transposon vector mutagenesis, and as a reporter for bacterial detection.

ADVANTAGE - (I) exhibits enhanced fluorescence relative to wild type GFP, when expressed in non-homologous cells at temperatures above 30 deg. C, and excited at 490 nm. (I) detects GFP reporters in mammalian cells at lower levels of expression with increased sensitivity relative to wild type GFP.

Dwg.0/7

ACCESSION NUMBER: 2003-095652 [09] WPIDS

DOC. NO. NON-CPI: N2003-075841 DOC. NO. CPI: C2003-024324

TITLE: Novel fluorescent protein derived

from green fluorescent protein useful

as a transfection marker, has different excitation spectrum and/or emission spectrum compared with wild-type

green fluorescent protein.

DERWENT CLASS: B04 D16 S03

INVENTOR(S): JONES, A E; MICHAEL, N P; STUBBS, S L J; THOMAS, N PATENT ASSIGNEE(S): (AMSH) AMERSHAM BIOSCIENCES UK LTD; (AMSH) AMERSHAM

PHARMACIA BIOTECH UK LTD; (JONE-I) JONES A E; (MICH-I) MICHAEL N P; (STUB-I) STUBBS S L J; (THOM-I) THOMAS N

COUNTRY COUNT: 9

98

PATENT INFORMATION:

PATENT NO KIND DATE WEEK LA PG

GB 2374868 A 20021030 (200309)* 52 WO 2002085936 A1 20021031 (200309) EN

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO

RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

GB 2374868 B 20030709 (200353)

US 2003175859 A1 20030918 (200362)

EP 1381625 A1 20040121 (200410) EN

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR

APPLICATION DETAILS:

PAT	TENT NO K	IND	API	PLICATION	DATE
GB	2374868	A	GB	2001-23288	20010928
WO	2002085936	Al	WO	2001-GB4363	20010928
GB	2374868	В	GB	2001-23288	20010928
US	2003175859	A1	US	2001-967301	20010928
ΕP	1381625	A1	ΕP	2001-972260	20010928
			WO	2001-GB4363	20010928

FILING DETAILS:

PATENT NO	KIND	PATENT NO
		
EP 1381625	Al Based on	WO 2002085936

PRIORITY APPLN. INFO: GB 2001-9858 20010423

=> d his

L1

(FILE 'HOME' ENTERED AT 14:46:22 ON 26 MAR 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT 14:46:40 ON 26 MAR 2004

27483 S FLUORESCENT PROTEIN AND GFP

L2 16 S MODIFIED GFP AND WILDTYPE

L3 16 S L1 AND L2

L4 51 S L1 AND "S175"

L5 4 S L4 AND "F64"

L6 2 S L4 AND "E222"

L7 66 S L1 AND "S65"

=> d 17 ti abs ibib 1-10

- L7 ANSWER 1 OF 66 MEDLINE on STN
- TI The extracellular N terminus of the endothelin B (ETB) receptor is cleaved by a metalloprotease in an agonist-dependent process.
- AB The extracellular N terminus of the endothelin B (ET(B)) receptor is susceptible to limited proteolysis (cleavage at R64 downward arrow \$65), but the regulation and the functional consequences of the proteolysis remain elusive. We analyzed the ET(B) receptor or an ET(B)-GFP fusion protein stably or transiently expressed in HEK293 cells. After incubation of cells at 4 degrees C, only the full-length ET(B) receptor was detected at the cell surface. However, when cells were incubated at 37 degrees C, N-terminal cleavage was observed, provided endothelin 1 was present during the incubation. Cleavage was not inhibited by internalization inhibitors (sucrose, phenylarsine oxide). However, in cells incubated with both internalization inhibitors and metalloprotease inhibitors (batimastat, inhibitor of TNFalpha-convertase) or metal chelators (EDTA, phenanthroline), the cleavage was blocked, indicating that metalloproteases cleave the agonist-occupied ET(B) receptor at the cell surface. Functional analysis of a mutant ET(B) receptor lacking the first 64 amino acids ([Delta2-64]ET(B) receptor) revealed normal functional properties, but a 15-fold reduced cell surface expression. The results suggest a role of the N-terminal proteolysis in

the regulation of cell surface expression of the ET(B) receptor. This is the first example of a multispanning membrane protein, which is cleaved by a metalloprotease, but retains its functional activity and overall

structure.

ACCESSION NUMBER: 2002684360 MEDLINE DOCUMENT NUMBER: PubMed ID: 12226103

TITLE: The extracellular N terminus of the endothelin B (ETB)

receptor is cleaved by a metalloprotease in an

agonist-dependent process.

AUTHOR: Grantcharova Evelina; Furkert Jens; Reusch H Peter; Krell

Hans-Willi; Papsdorf Gisela; Beyermann Michael; Schulein

Ralf; Rosenthal Walter; Oksche Alexander

CORPORATE SOURCE: Forschungsinstitut fur Molekulare Pharmakologie, Campus

Berlin Buch, Robert-Roessle-Strasse 10, 13125 Berlin,

Federal Republic of Germany.

SOURCE: Journal of biological chemistry, (2002 Nov 15) 277 (46)

43933-41.

Journal code: 2985121R. ISSN: 0021-9258.

PUB. COUNTRY:

United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200301

ENTRY DATE: Entered STN: 20021214

Last Updated on STN: 20030103 Entered Medline: 20030102

L7 ANSWER 2 OF 66 USPATFULL on STN

TI Human kinases

AB The invention provides human kinases (PKIN) and polynucleotides which identify and encode PKIN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonist. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PKIN.

ACCESSION NUMBER:

2004:76648 USPATFULL

TITLE:

Human kinases

INVENTOR(S):

Yang, Junming, San Jose, CA, UNITED STATES

Baughn, Mariah R., San Leandro, CA, UNITED STATES

Buford, Neil, Durham, CT, UNITED STATES

Au-Young, Janice, Brisbane, CA, UNITED STATES Lu, Dyung Aina M, San Jose, CA, UNITED STATES Reddy, Roopa, Sunnyvale, CA, UNITED STATES Yue, Henry, Sunnyvale, CA, UNITED STATES

Yao, Monique G, Mountain View, CA, UNITED STATES Lal, Preeti, Santa Clara, CA, UNITED STATES Khan, Farrah A, Des Plaines, IL, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004058426	A1	20040325	
APPLICATION INFO.:	US 2002-168582	A1	20020620	(10)
	WO 2000-US35304		20001220	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	INCYTE CORPORATION	I (for	merly known	as T

LEGAL REPRESENTATIVE: INCYTE CORPORATION (formerly known as Incyte, Genomics,

Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304

NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 6360

L7 ANSWER 3 OF 66 USPATFULL on STN

TI Enzymes involved in glycoprotein and glycolipid metabolism

AB The invention provides human enzymes involved in glycoprotein and

glycolipid metabolism (GLYCOS) and polynucleotides which identify and encode GLYCOS. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorder associated with aberrant expression of GLYCOS.

ACCESSION NUMBER:

2004:70606 USPATFULL

TITLE:

Enzymes involved in glycoprotein and glycolipid

metabolism

INVENTOR(S):

Lal, Preeti G, Santa Clara, CA, UNITED STATES

Yue, Henry, Sunnyvale, CA, UNITED STATES

Lu, Dyung Aina M., San Jose, CA, UNITED STATES Gandhi, Ameena R., San Francisco, CA, UNITED STATES Thangavelu, Kavitha, Sunnyvale, CA, UNITED STATES Chawla, Narinder K., Union City, CA, UNITED STATES Baughn, Mariah R., San Leandro, CA, UNITED STATES

	NUMBER	KIND	DATE			
PATENT INFORMATION:	US 2004053834	A1	20040318			
APPLICATION INFO.:	US 2003-415186	A1	20030423	(10)		
	WO 2001-US44973		20011030			
DOCUMENT TYPE:	Utility					
FILE SEGMENT:	APPLICATION					
LEGAL REPRESENTATIVE:	INCYTE CORPORATION	ON, 316	0 PORTER	DRIVE,	PALO ALTO), CA,
	94304					
NUMBER OF CLAIMS:	59					
EXEMPLARY CLAIM:	1					
LINE COUNT:	4821					

- L7 ANSWER 4 OF 66 USPATFULL on STN
- TI Human kinases

The invention provides human human kinases (PKIN) and polynucleotides which identify and encode PKIN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PKIN.

ACCESSION NUMBER:

TITLE:

INVENTOR(S):

2004:70167 USPATFULL

Human kinases

Gururajan, Rajagopal, SAN JOSE, CA, UNITED STATES Baughn, Mariah R, San Leandro, CA, UNITED STATES Chawla, Narinder K, Union City, CA, UNITED STATES Elliott, Vicki S, San Jose, CA, UNITED STATES Xu, Yuming, Mountain View, CA, UNITED STATES Arvizu, Chandra S, San Jose, CA, UNITED STATES Yao, Monique G, Carmel, INDIA

Ramkumar, Jayalaxmi, Femont, CA, UNITED STATES

Ding, Li, Creve Coeur, MO, UNITED STATES Tang, Y Tom, San Jose, CA, UNITED STATES

Hafalia, April J A, Daly City, CA, UNITED STATES Nguyen, Danniel B, San Jose, CA, UNITED STATES Gandhi, Ameena R, San Francisco, CA, UNITED STATES

Lu, Yan, Mountain View, CA, UNITED STATES Yue, Henry, Sunnyvale, CA, UNITED STATES Burford, Neil, Durham, CT, UNITED STATES

Bandman, Olga, Mountain View, CA, UNITED STATES Tribouley, Catherine M, San Francisco, CA, UNITED STATES

Lal, Preeti G, Santa Clara, CA, UNITED STATES
Recipon, Shirley A, San Francisco, CA, UNITED STATES
Lu, Dyung Aina M, San Jose, CA, UNITED STATES
Borowsky, Mark L, Northampton, MA, UNITED STATES
Thornton, Michael B, Oakland, CA, UNITED STATES

Swarnakar, Anita, San Francisco, CA, UNITED STATES Thangavelu, Kavitha, Sunnyvale, CA, UNITED STATES Khan, Farrah A, Des Plaines, IL, UNITED STATES Ison, Craig H, San Jose, CA, UNITED STATES

•	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004053394	Al	20040318	
APPLICATION INFO.:	US 2003-415011	A1	20030418	(10)
	WO 2001-US47728		20011020	
DOCUMENT TVDE.	IIt ility			

DOCUMENT TYPE: APPLICATION FILE SEGMENT:

LEGAL REPRESENTATIVE: INCYTE CORPORATION, 3160 PORTER DRIVE, PALO ALTO, CA,

94304

NUMBER OF CLAIMS: 99 EXEMPLARY CLAIM: 1 LINE COUNT: 9902

ANSWER 5 OF 66 USPATFULL on STN L7

Novel metalloprotease polypeptide, MP-1 ΤI

The present invention provides novel polynucleotides encoding MP-1 AΒ polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel MP-1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

2004:63784 USPATFULL ACCESSION NUMBER:

Novel metalloprotease polypeptide, MP-1 TITLE: Chen, Jian, Princeton, NJ, UNITED STATES INVENTOR(S):

Feder, John N., Belle Mead, NJ, UNITED STATES Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES Krystek, Stanley R., Ringoes, NJ, UNITED STATES

Duclos, Franck, Washington Crossing, PA, UNITED STATES

KIND DATE NUMBER ______ US 2004048302 A1 20040311 PATENT INFORMATION: A1 US 2003-651722 20030829 (10) APPLICATION INFO.: Division of Ser. No. US 2002-67443, filed on 5 Feb

RELATED APPLN. INFO.: 2002, GRANTED, Pat. No. US 6642041

> NUMBER DATE ______ US 2001-266518P 20010205 (60)

PRIORITY INFORMATION: 20010410 (60) US 2001-282814P DOCUMENT TYPE: Utility

APPLICATION FILE SEGMENT: LEGAL REPRESENTATIVE:

STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT

DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000

NUMBER OF CLAIMS: 32 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 43 Drawing Page(s)

LINE COUNT: 15444

ANSWER 6 OF 66 USPATFULL on STN L7

Lipid metabolism enzymes TТ

The invention provides human lipid metabolism enzymes (LMM) and ABpolynucleotides which identify and encode LMM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of LMM.

ACCESSION NUMBER:

TITLE:

INVENTOR(S):

2004:63751 USPATFULL

Lipid metabolism enzymes

Griffin, Jennifer A, Fremont, CA, UNITED STATES Arvizu, Chandra S, San Jose, CA, UNITED STATES Ammena R, Gandhi, San Francisco, CA, UNITED STATES

Lu, Yan, Palo Alto, CA, UNITED STATES Yao, Monique G, Carmel, IN, UNITED STATES

Baughn, Mariah R, San Leandro, CA, UNITED STATES Chawla, Narinder K, Union City, CA, UNITED STATES Hafalia, April J A, Santa Clara, CA, UNITED STATES

Ding, Li, Creve Coeur, MO, UNITED STATES

Tribouley, Catherine M, San Francisco, CA, UNITED

STATES

Utility

Das, Debopriya, Mountain View, CA, UNITED STATES Thornton, Michael B, Woodside, CA, UNITED STATES Lal, Preeti G, Santa Clara, CA, UNITED STATES

	NUMBER	KIND	DATE	
APPLICATION INFO.: U	S 2004048269 S 2003-362628 O 2001-US26365	A1 A1	20040311 20030221 20010822	(10)

DOCUMENT TYPE:

LINE COUNT:

FILE SEGMENT:

LEGAL REPRESENTATIVE:

APPLICATION INCYTE CORPORATION (formerly known as Incyte, Genomics,

Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304

NUMBER OF CLAIMS: EXEMPLARY CLAIM: 71 1 5637

L7 ANSWER 7 OF 66 USPATFULL on STN

TI Extracellular signaling molecules

The invention provides human extracellular signaling molecules (EXCS) and polynucleotides which identify and encode EXCS. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of EXCS.

ACCESSION NUMBER:

TITLE:

INVENTOR(S):

2004:63726 USPATFULL

Extracellular signaling molecules

Tang, Y. Tom, San Jose, CA, UNITED STATES Yue, Henry, Sunnyvale, CA, UNITED STATES Lal, Preeti, Santa Clara, CA, UNITED STATES Burford, Neil, Durham, CT, UNITED STATES

Bandman, Olga, Mountain View, CA, UNITED STATES
Baughn, Mariah R., San Leandro, CA, UNITED STATES
Azimzai, Yalda, Castro Valley, CA, UNITED STATES
Lu, Dyung Aina M., San Jose, CA, UNITED STATES
Arvizu, Chandra, Menlo Park, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004048244	A1	20040311	
APPLICATION INFO.:	US 2001-969984	A1	20011002	

DOCUMENT TYPE: FILE SEGMENT:

Utility APPLICATION

LEGAL REPRESENTATIVE:

INCYTE CORPORATION, 3160 PORTER DRIVE, PALO ALTO, CA,

(9)

94304

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

107 1 NUMBER OF DRAWINGS:

2 Drawing Page(s)

LINE COUNT:

ANSWER 8 OF 66 USPATFULL on STN Ь7

Alpha galalctosidase a: remodeling and glycoconjugation of alpha ΤI

galactosidase A

The invention includes methods and compositions for remodeling a peptide AB molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a

ACCESSION NUMBER:

2004:57444 USPATFULL

TITLE:

Alpha galalctosidase a: remodeling and glycoconjugation

of alpha galactosidase A

INVENTOR(S):

DeFrees, Shawn, North Wales, PA, UNITED STATES

Zopf, David, Wayne, PA, UNITED STATES

Bayer, Robert, San Diego, CA, UNITED STATES Bowe, Caryn, Doylestown, PA, UNITED STATES Hakes, David, Willow Grove, PA, UNITED STATES

PATENT ASSIGNEE(S):

Chen, Xi, Lansdale, PA, UNITED STATES Neose Technologies, Inc. (U.S. corporation)

NUMBER KIND DATE US 2004043446 A1 20040304 US 2003-411037 A1 20030409

PATENT INFORMATION: APPLICATION INFO.:

(10)

RELATED APPLN. INFO.:

Continuation-in-part of Ser. No. WO 2002-US32263, filed

on 9 Oct 2002, PENDING

NUMBER DATE _____ US 2002-407527P US 2002-404249P 20020828 (60) PRIORITY INFORMATION: 20020816 (60) US 2002-396594P 20020717 (60) US 2002-391777P 20020625 (60) US 2002-387292P 20020607 (60) Utility

DOCUMENT TYPE: FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,

PHILADELPHIA, PA, 19103-2921

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

122 1

NUMBER OF DRAWINGS:

497 Drawing Page(s)

LINE COUNT:

19395

ANSWER 9 OF 66 USPATFULL on STN L7

Polynucleotides encoding a novel metalloprotease, MP-1 TI

The present invention provides novel polynucleotides encoding MP-1 ΑB polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel MP-1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2004:57405 USPATFULL

TITLE:

Polynucleotides encoding a novel metalloprotease, MP-1

INVENTOR(S):

Chen, Jian, Princeton, NJ, UNITED STATES

Feder, John N., Belle Mead, NJ, UNITED STATES Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES

Krystek, Stanley R., Ringoes, NJ, UNITED STATES Duclos, Franck, Washington Crossing, PA, UNITED STATES

DATE KIND NUMBER -----

PATENT INFORMATION:

US 2004043407 A1 20040304 US 2003-649273 A1 20030827

APPLICATION INFO.: RELATED APPLN. INFO.:

(10) Continuation of Ser. No. US 2002-67443, filed on 5 Feb

2002, GRANTED, Pat. No. US 6642041

DATE NUMBER

PRIORITY INFORMATION:

US 2001-266518P 20010205 (60)

US 2001-282814P 20010410 (60)

DOCUMENT TYPE: FILE SEGMENT:

Utility APPLICATION

LEGAL REPRESENTATIVE:

STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT

DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000

NUMBER OF CLAIMS:

44 1

EXEMPLARY CLAIM: NUMBER OF DRAWINGS:

18 Drawing Page(s)

LINE COUNT:

15462

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 10 OF 66 USPATFULL on STN L7

Intracellular signaling molecules TI

The invention provides human intracellular signaling molecules (INTSIG) AB and polynucleotides which identify and encode INTSIG. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2004:57393 USPATFULL

TITLE:

Intracellular signaling molecules

Baughn, Mariah R, San Leandro, CA, UNITED STATES INVENTOR(S): Ding, Li, Creve Couer, MO, UNITED STATES Elliott, Vicki S, San Jose, CA, UNITED STATES Gandhi, Ameena R, San Francisco, CA, UNITED STATES Gietzen, Kimberly J, San Jose, CA, UNITED STATES Griffin, Jennifer A, Fremont, CA, UNITED STATES Gururajan, Rajagopal, San Jose, CA, UNITED STATES Hafalia, April J A, Daly City, CA, UNITED STATES Kearney, Liam, San Francisco, CA, UNITED STATES

Khan, Farrah A, Des Plaines, IL, UNITED STATES Lal, Preeti G, Santa Clara, CA, UNITED STATES Lee, Ernestine A, Castro Valley, CA, UNITED STATES M Lu, Dyung Aina, San Jose, CA, UNITED STATES

Lu, Yan, Mountain View, CA, UNITED STATES Nguyen, Danniel B, San Jose, CA, UNITED STATES Arvizu, Chandra S, San Jose, CA, UNITED STATES Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES

Yue, Henry, Sunnyvale, CA, UNITED STATES

Tang, Y Tom, San Jose, CA, UNITED STATES Thangavelu, Kavitha, Sunnyvale, CA, UNITED STATES Thornton, Michael B, Oakland, CA, UNITED STATES Chawla, Narinder K, Union City, CA, UNITED STATES Warren, Bridget A, Encinitas, CA, UNITED STATES Xu, Yuming, Mountain View, CA, UNITED STATES Yao, Monique G, Carmel, IN, UNITED STATES

NUMBER KIND DATE _____ PATENT INFORMATION: US 2004043395 **A1** 20040304

US 2003-399456 APPLICATION INFO.: **A1** 20030414 (10)

WO 2001-US32090 20011012

DOCUMENT TYPE: Utility FILE SEGMENT: APPLICATION

INCYTE CORPORATION, 3160 PORTER DRIVE, PALO ALTO, CA, LEGAL REPRESENTATIVE:

94304

NUMBER OF CLAIMS: 95 EXEMPLARY CLAIM: 1 LINE COUNT: 6007

CAS INDEXING IS AVAILABLE FOR THIS PATENT.